Merck Sharp + Dohme Corp.

Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Pharmacopeia Inc.

Youheng Shu

Joseph A Kozlowski

Michael K C Wong

Zhi-Qiang Yang

Scott D Kuduk

Neng-Yang Shih

Ling Tong

Robert S Meissner

James J Perkins

Douglas C Beshore

Bandarpalle B Shankar

Michael T Rudd

Brian J Lavey

Peter J Manley

Richard J Friary

Guowei Zhou

Lei Chen

Christopher James Bungard

Zhaoyang Meng

Timothy John Hartingh

Barbara Hanney

Antonella Converso

Jesse J Manikowski

Pablo De Leon

Paul J Coleman

Stuart B Rosenblum

Wensheng Yu

James C Barrow

Douglas Walsh Hobbs

Brian F McGuinness

Thomas S Reger

Yuefei Shao

Zhiqiang Yang

Kelly-Ann S Schlegel

Daniel Pitts

Rowena V Cube

Jesse Josef Manikowski

Mamio Christa Merck & Co Inc Mattern

Kelly-Ann S Merck & Co Inc Bieber

The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) 

Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use

The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

N-linked lactam M1 receptor positive allosteric mogulators

The present invention is directed to isoindolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

Isoindolone M1 receptor positive allosteric modulators

The present invention is directed to heterocycle phenyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. 

Heterocycle phenyl amide T-type calcium channel antagonists

There are disclosed compounds of the formula I: or a pharmaceutically acceptable salt of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.

Cannabinoid receptor ligands

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity

There are disclosed compounds of the formula I:or a pharmaceutically acceptable salt of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.

Growing community of inventors

Blue Bell, PA, United States of America

Youheng Shu